Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for IO Biotech, Inc. (IOBT : NSDQ)

• Company Description    IO Biotech Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel, immune-modulating cancer therapies based on its T-win(R) technology platform. IO Biotech Inc. is based in WILMINGTON, Del. Number of Employees: 80

• Price / Volume Information    Yesterday's Closing Price: $1.40 Daily Weekly Monthly 20 Day Moving Average: 148,813 shares Shares Outstanding: 65.88 (millions) Market Capitalization: $92.23 (millions) Beta: 0.36 52 Week High: $1.73 52 Week Low: $0.66 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.67% -10.16% 12 Week 62.77% 36.91% Year To Date 52.17% 42.51%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL OLE MAALOES VEJ 3 - COPENHAGEN,G7 2200 DNK ph: 45-7070-2980 fax: - info@iobiotech.com http://www.iobiotech.com

• General Corporate Information    Officers Mai-Britt Zocca - Chief Executive Officer and Director Peter Hirth - Chairman of the Board Amy Sullivan - Chief Financial Officer Brian Burkavage - Chief Accounting Officer Kathleen Sereda Glaub - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 449778109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 65.88 Most Recent Split Date: (:1) Beta: 0.36 Market Capitalization: $92.23 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.35 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.27 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.49 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -13.33% vs. Previous Quarter: 29.17% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -162.55 12/31/24 - -115.29 ROA 06/30/25 - - 03/31/25 - -125.08 12/31/24 - -96.15 Current Ratio 06/30/25 - - 03/31/25 - 2.32 12/31/24 - 3.33 Quick Ratio 06/30/25 - - 03/31/25 - 2.32 12/31/24 - 3.33 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.40 12/31/24 - 0.71 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©